The U.S. Food and Drug Administration (FDA) has formally recommended that 7-hydroxymitragynine (7-OH), a potent opioid compound, be classified as a Schedule I illicit substance. The recommendation, announced on July 29, 2025, has been forwarded to the Drug Enforcement Administration (DEA), which holds the final authority on scheduling controlled substances.
This move targets concentrated 7-OH products, which are often sold in forms like gummies, tablets, and drink mixes at gas stations, vape shops, and online. Federal officials have voiced growing alarm over the substance’s potential for abuse and its role in the ongoing opioid crisis. “Dark innovations in chemistry have exacerbated the addiction crisis in this country,” said U.S. Department of Health and Human Services (HHS) Deputy Secretary Jim O’Neil during a press conference. He described 7-OH as a “powerful opioid agonist many times more potent than morphine” and a “recipe for public health disaster.”
What is 7-Hydroxymitragynine?
7-hydroxymitragynine is a terpenoid indole alkaloid that is naturally present in the leaves of the kratom plant, Mitragyna speciosa. However, it is only a minor component, typically making up less than 2% of the total alkaloid content in natural kratom leaves, according to an FDA report. The products causing concern are not natural kratom leaves but rather highly concentrated, often synthetically produced or enhanced, versions of 7-OH.
Scientifically, 7-OH is also a key active metabolite of mitragynine, the most abundant alkaloid in kratom. Research published by the National Institutes of Health (NIH) shows that when a person consumes mitragynine, the liver metabolizes it into the more potent 7-OH. This conversion is mediated by cytochrome P450 enzymes. The compound acts as a partial agonist at the μ-opioid receptors in the brain, the same receptors targeted by morphine and other opioids, which are responsible for effects like pain relief, euphoria, and potentially dangerous respiratory depression.
Regulatory Action and Public Health Concerns
The FDA’s recommendation is a response to what officials describe as a “disturbing rise in reports of overdoses, poisonings and emergency room visits linked to products containing 7-OH.” In a press release, the agency highlighted that these products are sold with no quality control, dosage information, or warnings, and are often packaged in forms that appeal to young people, such as fruit-flavored gummies.
“7-OH is an opioid that can be more potent than morphine. We need regulation and public education to prevent another wave of the opioid epidemic,” said FDA Commissioner Marty Makary, M.D., M.P.H. HHS Secretary Robert F. Kennedy, Jr., added, “Today, we’re taking action on 7-OH as a critical step in the fight against opioid addiction.”
The FDA has clarified that its action is specifically aimed at these concentrated 7-OH products and will not affect the legal status of the Mitragyna speciosa plant itself, which is expected to remain unscheduled at the federal level. This distinction is crucial, as many advocates separate the use of traditional, natural kratom leaf from the consumption of these new, highly potent extracts. Even the American Kratom Association, a consumer advocacy group, has issued alerts about synthetic 7-OH products, warning that any product with 7-OH levels exceeding 2% of the total alkaloid content should not be considered kratom.
The Path Forward
With the FDA’s recommendation submitted, the DEA will now conduct its own review. The process for scheduling a substance under the Controlled Substances Act requires a formal rulemaking procedure, which will include a period for public comment before a final decision is made. If the DEA concurs with the FDA’s findings, 7-OH will be placed into Schedule I, a category reserved for drugs with a high potential for abuse and no currently accepted medical use. In June, the FDA had already issued warning letters to seven companies for illegally distributing products containing 7-OH.
